Publisher: Wiley-Blackwell

Related content
Volume 13, Number 11, 1 November 2011

< previous issue | all issues | next issue >

Favourites:Add to Favourites

Glucagon antagonism as a potential therapeutic target in type 2 diabetes
pp. 965-971(7)
Authors: Bagger, J. I.; Knop, F. K.; Holst, J. J.; Vilsbøll, T.

Favourites:Add to Favourites
Favourites:Add to Favourites

GLP‐1 signals via ERK in peripheral nerve and prevents nerve dysfunction in diabetic mice
pp. 990-1000(11)
Authors: Jolivalt, C. G.; Fineman, M.; Deacon, C. F.; Carr, R. D.; Calcutt, N. A.

Favourites:Add to Favourites

Short‐term metabolic effects of prednisone administration in healthy subjects
pp. 1001-1007(7)
Authors: Kauh, E. A.; Mixson, L. A.; Shankar, S.; McCarthy, J.; Maridakis, V.; Morrow, L.; Heinemann, L.; Ruddy, M. K.; Herman, G. A.; Kelley, D. E.; Hompesch, M.

Favourites:Add to Favourites

A randomized, parallel group, double‐blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone/metformin) and metformin on long‐term glycaemic control and bone mineral density after 80 weeks of treatment in drug‐na
pp. 1036-1046(11)
Authors: Borges, J. L. C.; Bilezikian, J. P.; Jones‐Leone, A. R.; Acusta, A. P.; Ambery, P. D.; Nino, A. J.; Grosse, M.; Fitzpatrick, L. A.; Cobitz, A. R.

Favourites:Add to Favourites

Effects of a long‐acting GLP‐1 mimetic (PF‐04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus
pp. 1056-1058(3)
Authors: Gustavson, S. M.; Chen, D.; Somayaji, V.; Hudson, K.; Baltrukonis, D. J.; Singh, J.; Boyden, T. L.; Calle, R. A.

Favourites:Add to Favourites

News and views
pp. 1059-1061(3)
Author: Idris, Iskandar

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more